Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients

Akihiro Himeno, Noriko Satoh-Asahara, Takeshi Usui, Hiromichi Wada, Mayu Tochiya, Shigeo Kono, Nobuko Goto, Goro Katsuura, Koji Hasegawa, Kazuwa Nakao, Akira Shimatsu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis can increase the risk of cardiovascular disease (CVD). However, the detailed relationships of HPA axis activity with weight reduction and CVD risk factors in obese patients have not been examined. This study was designed to elucidate the associations of salivary cortisol levels with weight reduction and CVD risk factors in obese patients. As a marker of HPA axis activity, we measured the morning salivary cortisol levels of 83 obese Japanese outpatients. We also examined metabolic parameters, inflammatory markers, and indicators of arterial stiffness, that is, the pulse wave velocity and cardio-ankle vascular index. All 83 obese patients underwent 3-month weight reduction therapy with lifestyle modification. At the baseline, multivariate regression analysis revealed that only logarithmic transformation of C-reactive protein (β = 0.258, P <.05) and cardio-ankle vascular index (β = 0.233, P <.05) were independent determinants of the salivary cortisol levels. However, other metabolic parameters were not significantly associated with the salivary cortisol levels. In addition, lower salivary cortisol levels and higher body weight at the baseline were the only independent determinants of successful weight loss through the weight reduction therapy (P <.01). The present study demonstrates that the baseline morning salivary cortisol levels are significantly associated with the levels of an inflammatory marker, arterial stiffness, and successful weight reduction in obese patients. Therefore, salivary cortisol could be a useful marker for assessing and managing body weight and CVD risk factors in obese patients.

Original languageEnglish
Pages (from-to)255-261
Number of pages7
JournalMetabolism: Clinical and Experimental
Volume61
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1
Externally publishedYes

Fingerprint

Hydrocortisone
Weight Loss
Cardiovascular Diseases
Vascular Stiffness
Ankle
Therapeutics
Blood Vessels
Body Weight
Pulse Wave Analysis
C-Reactive Protein
Life Style
Outpatients
Multivariate Analysis
Regression Analysis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients. / Himeno, Akihiro; Satoh-Asahara, Noriko; Usui, Takeshi; Wada, Hiromichi; Tochiya, Mayu; Kono, Shigeo; Goto, Nobuko; Katsuura, Goro; Hasegawa, Koji; Nakao, Kazuwa; Shimatsu, Akira.

In: Metabolism: Clinical and Experimental, Vol. 61, No. 2, 01.02.2012, p. 255-261.

Research output: Contribution to journalArticle

Himeno, A, Satoh-Asahara, N, Usui, T, Wada, H, Tochiya, M, Kono, S, Goto, N, Katsuura, G, Hasegawa, K, Nakao, K & Shimatsu, A 2012, 'Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients', Metabolism: Clinical and Experimental, vol. 61, no. 2, pp. 255-261. https://doi.org/10.1016/j.metabol.2011.06.023
Himeno, Akihiro ; Satoh-Asahara, Noriko ; Usui, Takeshi ; Wada, Hiromichi ; Tochiya, Mayu ; Kono, Shigeo ; Goto, Nobuko ; Katsuura, Goro ; Hasegawa, Koji ; Nakao, Kazuwa ; Shimatsu, Akira. / Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients. In: Metabolism: Clinical and Experimental. 2012 ; Vol. 61, No. 2. pp. 255-261.
@article{12eb775a5006413b888b8f878585413b,
title = "Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients",
abstract = "Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis can increase the risk of cardiovascular disease (CVD). However, the detailed relationships of HPA axis activity with weight reduction and CVD risk factors in obese patients have not been examined. This study was designed to elucidate the associations of salivary cortisol levels with weight reduction and CVD risk factors in obese patients. As a marker of HPA axis activity, we measured the morning salivary cortisol levels of 83 obese Japanese outpatients. We also examined metabolic parameters, inflammatory markers, and indicators of arterial stiffness, that is, the pulse wave velocity and cardio-ankle vascular index. All 83 obese patients underwent 3-month weight reduction therapy with lifestyle modification. At the baseline, multivariate regression analysis revealed that only logarithmic transformation of C-reactive protein (β = 0.258, P <.05) and cardio-ankle vascular index (β = 0.233, P <.05) were independent determinants of the salivary cortisol levels. However, other metabolic parameters were not significantly associated with the salivary cortisol levels. In addition, lower salivary cortisol levels and higher body weight at the baseline were the only independent determinants of successful weight loss through the weight reduction therapy (P <.01). The present study demonstrates that the baseline morning salivary cortisol levels are significantly associated with the levels of an inflammatory marker, arterial stiffness, and successful weight reduction in obese patients. Therefore, salivary cortisol could be a useful marker for assessing and managing body weight and CVD risk factors in obese patients.",
author = "Akihiro Himeno and Noriko Satoh-Asahara and Takeshi Usui and Hiromichi Wada and Mayu Tochiya and Shigeo Kono and Nobuko Goto and Goro Katsuura and Koji Hasegawa and Kazuwa Nakao and Akira Shimatsu",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.metabol.2011.06.023",
language = "English",
volume = "61",
pages = "255--261",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients

AU - Himeno, Akihiro

AU - Satoh-Asahara, Noriko

AU - Usui, Takeshi

AU - Wada, Hiromichi

AU - Tochiya, Mayu

AU - Kono, Shigeo

AU - Goto, Nobuko

AU - Katsuura, Goro

AU - Hasegawa, Koji

AU - Nakao, Kazuwa

AU - Shimatsu, Akira

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis can increase the risk of cardiovascular disease (CVD). However, the detailed relationships of HPA axis activity with weight reduction and CVD risk factors in obese patients have not been examined. This study was designed to elucidate the associations of salivary cortisol levels with weight reduction and CVD risk factors in obese patients. As a marker of HPA axis activity, we measured the morning salivary cortisol levels of 83 obese Japanese outpatients. We also examined metabolic parameters, inflammatory markers, and indicators of arterial stiffness, that is, the pulse wave velocity and cardio-ankle vascular index. All 83 obese patients underwent 3-month weight reduction therapy with lifestyle modification. At the baseline, multivariate regression analysis revealed that only logarithmic transformation of C-reactive protein (β = 0.258, P <.05) and cardio-ankle vascular index (β = 0.233, P <.05) were independent determinants of the salivary cortisol levels. However, other metabolic parameters were not significantly associated with the salivary cortisol levels. In addition, lower salivary cortisol levels and higher body weight at the baseline were the only independent determinants of successful weight loss through the weight reduction therapy (P <.01). The present study demonstrates that the baseline morning salivary cortisol levels are significantly associated with the levels of an inflammatory marker, arterial stiffness, and successful weight reduction in obese patients. Therefore, salivary cortisol could be a useful marker for assessing and managing body weight and CVD risk factors in obese patients.

AB - Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis can increase the risk of cardiovascular disease (CVD). However, the detailed relationships of HPA axis activity with weight reduction and CVD risk factors in obese patients have not been examined. This study was designed to elucidate the associations of salivary cortisol levels with weight reduction and CVD risk factors in obese patients. As a marker of HPA axis activity, we measured the morning salivary cortisol levels of 83 obese Japanese outpatients. We also examined metabolic parameters, inflammatory markers, and indicators of arterial stiffness, that is, the pulse wave velocity and cardio-ankle vascular index. All 83 obese patients underwent 3-month weight reduction therapy with lifestyle modification. At the baseline, multivariate regression analysis revealed that only logarithmic transformation of C-reactive protein (β = 0.258, P <.05) and cardio-ankle vascular index (β = 0.233, P <.05) were independent determinants of the salivary cortisol levels. However, other metabolic parameters were not significantly associated with the salivary cortisol levels. In addition, lower salivary cortisol levels and higher body weight at the baseline were the only independent determinants of successful weight loss through the weight reduction therapy (P <.01). The present study demonstrates that the baseline morning salivary cortisol levels are significantly associated with the levels of an inflammatory marker, arterial stiffness, and successful weight reduction in obese patients. Therefore, salivary cortisol could be a useful marker for assessing and managing body weight and CVD risk factors in obese patients.

UR - http://www.scopus.com/inward/record.url?scp=84856081199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856081199&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2011.06.023

DO - 10.1016/j.metabol.2011.06.023

M3 - Article

C2 - 21871641

AN - SCOPUS:84856081199

VL - 61

SP - 255

EP - 261

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 2

ER -